PURPOSE: The purpose of this analysis was to develop a population pharmacokinetic model for farletuzumab, a humanized immunoglobulin (Ig)G(1) monoclonal antibody (mAb) to the folate receptor alpha, which is a receptor over-expressed in ovarian cancer, but largely absent from normal tissue. METHODS: In total, 2,472 samples were included in the building of the pharmacokinetic model. Farletuzumab 12.5-400 mg/m(2) had been administered via intravenous infusion to 79 patients with advanced ovarian cancer enrolled in one of the two clinical studies. Data were analyzed by a nonlinear mixed-effects modeling approach. RESULTS: Farletuzumab pharmacokinetics was best described by a two-compartment model with first-order (linear) elimination. In the final model, estimated values of clearance and volume of distribution of the central compartment were 0.00784 l/h and 3.00 l, respectively. Body weight was the only covariate investigated that explained inter-patient variability in clearance and the central volume of distribution. There was no effect of age, human anti-human antibodies, or concomitant chemotherapy on the pharmacokinetics of farletuzumab. Simulations showed that, when the mg/kg/week dose was maintained, steady-state exposure to farletuzumab was similar with dosing every week or every 3 weeks. CONCLUSIONS: The pharmacokinetic parameters of farletuzumab are similar to those of other IgG mAbs. The results support weight-based dosing of farletuzumab on a weekly or 3-weekly schedule.
PURPOSE: The purpose of this analysis was to develop a population pharmacokinetic model for farletuzumab, a humanized immunoglobulin (Ig)G(1) monoclonal antibody (mAb) to the folate receptor alpha, which is a receptor over-expressed in ovarian cancer, but largely absent from normal tissue. METHODS: In total, 2,472 samples were included in the building of the pharmacokinetic model. Farletuzumab 12.5-400 mg/m(2) had been administered via intravenous infusion to 79 patients with advanced ovarian cancer enrolled in one of the two clinical studies. Data were analyzed by a nonlinear mixed-effects modeling approach. RESULTS:Farletuzumab pharmacokinetics was best described by a two-compartment model with first-order (linear) elimination. In the final model, estimated values of clearance and volume of distribution of the central compartment were 0.00784 l/h and 3.00 l, respectively. Body weight was the only covariate investigated that explained inter-patient variability in clearance and the central volume of distribution. There was no effect of age, human anti-human antibodies, or concomitant chemotherapy on the pharmacokinetics of farletuzumab. Simulations showed that, when the mg/kg/week dose was maintained, steady-state exposure to farletuzumab was similar with dosing every week or every 3 weeks. CONCLUSIONS: The pharmacokinetic parameters of farletuzumab are similar to those of other IgG mAbs. The results support weight-based dosing of farletuzumab on a weekly or 3-weekly schedule.
Authors: Nikki Parker; Mary Jo Turk; Elaine Westrick; Jeffrey D Lewis; Philip S Low; Christopher P Leamon Journal: Anal Biochem Date: 2005-03-15 Impact factor: 3.365
Authors: Daniel J O'Shannessy; Elizabeth B Somers; Earl Albone; Xin Cheng; Young Chul Park; Brian E Tomkowicz; Yoshitomo Hamuro; Thomas O Kohl; Tracy M Forsyth; Robert Smale; Yao-Shi Fu; Nicholas C Nicolaides Journal: Oncotarget Date: 2011-12
Authors: Allison G Roy; J Michael Robinson; Prannda Sharma; Alba Rodriguez-Garcia; Mathilde A Poussin; Cheryl Nickerson-Nutter; Daniel J Powell Journal: Int J Mol Sci Date: 2021-05-25 Impact factor: 5.923
Authors: Elisabeth Smolle; Valentin Taucher; Martin Pichler; Edgar Petru; Sigurd Lax; Johannes Haybaeck Journal: Int J Mol Sci Date: 2013-05-02 Impact factor: 5.923
Authors: Cristina Martín-Sabroso; Ana Isabel Torres-Suárez; Mario Alonso-González; Ana Fernández-Carballido; Ana Isabel Fraguas-Sánchez Journal: Pharmaceutics Date: 2021-12-22 Impact factor: 6.321